January 27, 2023

Merck Animal Health Receives FDA Approval for Expanded Indication for BRAVECTO Chews for Dogs

Merck Animal Health, a division of Merck & Co., Inc., has received FDA approval for an expanded indication for BRAVECTO Chews for Dogs. The new indication treats and controls Asian longhorned ticks, which are an invasive Ixodid species located across more than one-third of the US.

BRAVECTO Chews for Dogs is the first and only US product labeled for the treatment and control of Asian long-horned tick infestations. These ticks have the potential to quickly become an important tick species within pet populations and have been known to carry various viral, bacterial and protozoal agents.

“The approval of this additional BRAVECTO use builds on the strong foundation and body of scientific evidence that we have established throughout the years with our broad-spectrum comprehensive line of parasite protection products,” said Holger Lehmann, VP of Pharmaceutical Research and Development, Merck Animal Health. “With BRAVECTO’s new indication in Asian long-horned ticks, we have expanded our portfolio with an important claim in the fight against parasites, as well as provided dogs with flea and tick protection that delivers immediate and persistent killing activity.”

BRAVECTO Chews for dogs is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis), treatment and control of tick infestations (Ixodes scapularis (black-legged tick), Dermacentor variabilis (American dog tick), Rhipicephalus sanguineus (brown dog tick)] and Haemaphysalis longicornis (Asian long-horned tick) for 12 weeks and treatment and control of Amblyomma Americanum (lone star tick) infestations for eight weeks.

“Parasites pose serious animal and human health risks as fleas and ticks can transmit disease agents,” said Kathryn Duncan, Parasitology Field Specialist, Merck Animal Health. “Protection against the Asian long-horned tick is critical because its prevalence is increasing throughout the country. This expanded indication from Merck Animal Health represents a scientific milestone in our continued commitment to providing the highest level of proven treatments in battling parasites faced by our pets.”

BRAVECTO Chews for Dogs is part of the Merck Animal Health Companion Animal portfolio, which includes a broad range of veterinary medicines and vaccines, as well as the SURE PETCARE brand platform of digitally connected products along with the HomeAgain® brand-leading service provider in pet recovery.

BRAVECTO Chews for Dogs is available in five strengths (112.5, 250, 500, 1000 and 1400 mg fluralaner) per chew.

To learn more about BRAVECTO, click here.




Subscribe to Pet Insight